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Aim: To investigate the association of MDM2 expression at the mRNA levels in neuroblastoma with clinical features and unfavorable 
disease factors to determine the possibility of it usage as a prognostic marker of neuroblastoma. Materials and Methods: Total RNA 
and DNA were extracted from tumor tissue samples of total 91 neuroblastoma patients (mean age: 39.45 ± 4.81 months). MDM2 mRNA 
levels were detected with Q-PCR. TP53 gene deletion was detected with FISH method. MYCN amplification was detected with  Q-PCR 
analysis in fresh tumor samples and FISH in FFPE samples. Results: We investigated the association of MDM2 mRNA expression 
with clinical outcome in neuroblastoma patients (n = 91). Kaplan — Meier curves showed a significant association of high MDM2 ex-
pression with poor event-free survival (p < 0.001). Clinical outcome of patients without MYCN amplification with low MDM2 expres-
sion was associated with better event-free survival than with high MDM2 expression (p < 0.001). Overexpression of MDM2 can 
be used as significant prognostic marker for patient stratification on risk groups and treatment optimization. Conclusion: Our results 
showed that the high expression of MDM2 at mRNA levels is an important factor of neuroblastoma prognosis. It may be a valuable 
additional molecular marker in guiding specific therapy in MYCN non-amplified NB patients without TP53 gene deletion.
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Neuroblastoma (NB) is an embryonal tumor ari-
sing in tissues of the sympathetic nervous system and 
the most common cancer diagnosed during the first 
year of life. NB accounts for 15% of all deaths due 
to childhood malignancies. Despite intense multimo-
dality therapy, at least half of high-risk patients relapse 
that is almost always fatal [1]. Much of the difficulty 
in devising effective therapies for this latter group 
of patients lies in the heterogeneity of disease, which 
can be attributed largely to the interaction of multiple 
genetic and epigenetic factors [2].
Unlike many adult malignancies most NB do initially 
respond to chemotherapy and it is likely that the pre sence 
of functionally active p53 is at least partly involved in this 
initial chemosensitivity. However, over half of previously 
responsive NB eventually relapses with chemoresistant 
disease and there is evidence for p53 inactivation at this 
stage in some cases [3]. p53 is a potent transcription 
factor that modulates a large number of genes involved 
in apoptosis, metabolism, epigenetics, and cell cycle 
regulation [4]. p53 is usually expressed at low levels 
in the cell where it has a short half-life of only 30 min [5]. 
NB is a p53 wild type malignancy at diagnosis and re-
pression of p53 signaling plays an important role in its 
pathogenesis. Chemotherapy induces apoptosis and 
tumor regression primarily through activation of p53-
mediated transcription. A number of previous obser-
vations confirm that wild-type p53 alleles are present 
in the vast majority of cases of newly diagnosed NB, but 
that p53/MDM2/adenosine diphosphate-ribosylation 
factor (ARF) responses to chemotherapy are repressed, 
in part due to unscheduled inhibition of p53 by MDM2. 
This suggests that downregulation of the p53 axis may 
underlie the treatment resistance typically seen in high-
risk NB [4]. The expression, function and stabilization 
of p53 are governed by a complex network, which in-
cludes its regulators p14ARF and MDM2 [5].
Originally identiﬁed as an ampliﬁed gene located 
on a double minute chromosome in a transformed 
mouse cell line, MDM2 was later shown to have a critical 
role in the process of cellular transformation. Thus, de-
regulation of MDM2 gene expression likely contributes 
to the pathogenesis of a wide range of human tumors. 
Ampliﬁcation and/or overexpression of MDM2 is found 
in about 10% of all human tumors. In gliomas, for exam-
ple, MDM2 ampliﬁcation identiﬁes a subset of high-risk 
patients that do not have p53 mutations [6]. In many soft 
tissue sarcomas, MDM2 ampliﬁcation and overexpres-
sion correlates with poor prognosis.
Additionally, p53 activates the MDM2 gene that 
encodes p53 antagonist forming an autoregulatory 
feedback loop that tightly controls expression of both 
p53 and MDM2 [7]. MDM2 helps to target p53 for 
degradation through its E3 ubiquitin ligase activity.
Recent literature demonstrates that p53 is ge-
nerally functional, accumulates in the nucleus in re-
sponse to DNA damage and is efficiently degraded 
by MDM2 in NB cells. There are reports that p53 function 
may be compromised as a consequence of  aberrant 
MDM2 expression levels in NB. For instance, a study exa-
mining etoposide-induced p53  activity in a NB cell lines 
suggested an important role for elevated MDM2 expres-
sion levels in the regulation of p53 nuclear-cytoplasm 
translocation [8].
Also, elevated MDM2 expression and accompa-
nying loss of p53 function is associated with multidrug 
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resistance in some NB cell lines. MDM2 ubiquitin 
ligase activity is rate-limiting for p53 degradation 
and is critical in NB [9]. Taken together, these data 
demonstrate that the MDM2/p53 interaction is intact 
in NB and suggest that deﬁciencies in p53 functions 
may be a consequence of aberrant MDM2 expression.
Amplification of the MYCN gene (MNA) has 
emerged as one of the most reliable indicators 
of aggressive and treatment-resistant NB, yet 30% 
to 40% of high-risk tumors lack this feature [1]. MNA 
is associated with an exceptionally poor prognosis 
in NB. Furthermore, the crucial effectors of MYCN 
responsible for this aggressive subset of NB await 
characterization [8]. MYC oncogenes activate both 
proliferative and apoptotic cellular pathways and, 
accordingly, inhibition of p53-mediated apoptosis 
is a prerequisite for MYC-driven tumorigenesis [10]. 
A critical negative regulator of the p53 tumor suppres-
sor, MDM2, has been recently characterized in NB cell 
lines as a transcriptional target of MYCN. Targeted in-
hibition of MYCN results in reduced MDM2 expression 
levels, with concomitant stabilization of p53 and stimu-
lation of apoptosis in MNA NB cell lines [8]. Moreover, 
MDM2 has a p53-independent role in the regulation 
of both MYCN mRNA stabilization and its translation, 
suggesting that MDM2-mediated MYCN expression 
is one mechanism associated with growth of MYCN-
associated NB and disease progression [11]. MYCN 
also transcriptionally upregulates p53 expression 
in NB and may be an important mechanism by which 
MYCN induces apoptosis [12]. Scheme of MDM2 and 
p53 regulation involving MYCN is shown in Fig. 1.
Fig. 1. Scheme of MDM2 and p53 regulation involving MYCN 
oncogene
In this article, we have investigated the association 
of MDM2 mRNA expression in NB with clinical charac-
teristics and unfavorable disease factors (occurrence 
age, disease stage, MYCN gene status, metastases 
and relapses) to determine the possibility of it usage 
as a prognostic marker of NB.
MATERIALS AND METHODS
Patients. 91 patients with verified diagnosis 
of NB have been enrolled into this study. The age of pa-
tients ranged from 1 month to 17 years. Mean age was 
39.45 ± 4.81 months. Age of 28.6% patients did not 
exceed 18 months. Stages distribution: I–II stage — 
21.25% of patients, III stage — 22.5% of patients, 
IV stage — 56.25% of patients. All patients were 
treated in accordance with international standards 
of treatment for NB. Informed consent was obtained 
according to the requirements of the Ethics Commis-
sion of the National Cancer Institute.
Material. Tumor tissue material was obtained 
by biopsy or tumor resection. 87.9% of samples were 
obtained from primary NB tumors, 4.4% — from re-
current tumors, 7.7% — from metastatic focus. All 
biomaterial was taken before treatment. Fresh tumor 
samples for Q-PCR analysis were stored in “RNA-later” 
(“Ambion”, USA) to stabilize the RNA and DNA; for 
fluorescent in situ hybridization (FISH) formalin-fixed, 
paraffin embedded tissue (FFPE) samples were used.
Analysis of TP53 gene deletion. Deletion 
of TP53 gene was investigated in NB tumors using FISH 
analysis. Preparation of FFPE tissue sample slides was 
performed using Paraffin Pretreatment Reagent Kit 
I (Abbott, USA). FISH analysis was performed  using 
dual-color Vysis LSI p53 (17p13.1)/СЕР17 Probe (Ab-
bott, USA). Analysis of the hybridization was carried 
out using a fluorescence microscope Axio Imager 
M1 (Zeiss, Germany).
Analysis of MNA. Determination of MYCN gene 
status was assessed in NB fresh tumors by Q-PCR 
analysis and FISH for FFPE samples. Genomic DNA 
from tumor samples was isolated using “NucleoSpin 
Tissue” (Macherey-Nagel, Germany). Sequences 
of primers were experimentally selected with Primer 
Express® Software v3.0 (Applied Biosystems, USA) and 
synthesized by “Applied Biosystems”, they are shown 
in the Table 1. Primers and TaqMan probes were used 
at 0.6 μM and 0.4 μM concentrations, respectively. 
TaqMan Universal PCR Master Mix (Applied Byosys-
tems, USA) and 5 ng of DNA were used to prepare 
the reaction mixture in a total volume of 25 μl. 45 cycles 
real-time PCR (94 °C — 3 sec, 60 °C — 30 sec and 
72 °C — 30 sec) were run on 7300/7500 Real-Time PCR 
Systems, “Applied Biosystems”, USA. MYCN gene 
copy number was calculated by the formula:
x = 2-ΔCt,
where x — MYCN copy number, 
ΔCt = Ct (β-actin) − Ct (MYCN).
FISH analysis was performed using dual-color Vysis 
LSI® N-MYC Spectrum Green/CEP 2 Spectrum Orange™ 
(Abbott, USA). According to the European Network for 
Quality Assurance in Higher Education guidelines [13], 
MNA was defined as >4-fold increase of MYCN signal 
number in relation to the number of chromosome 2.
Table 1. Sequences of primers (F — forward, R — reverse) for PCR analysis
MYCN F: 5'СССCTGGGTCTGCCCCGTTT3'
R: 3'GGCGAAGTAGAAGTCATCTT5'
β-actin F: 5'TCACCCACACTGTGCCCATCTACGA3'
R: 3'CAGCGGAACCGCTCATTGCCAATGA5'
MDM2 F: 5'CGACTCCAAGCGCGAAA3'
R: 3'GGTTACAGCACCATCAGTAGGTACA5'
GADPH F: 5'TCACCCACACTGTGCCCATCTACGA3'
R: 3'CAGCGGAACCGCTCATTGCCAATGA5'
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Detection of MDM2 mRNA expression level. 
RNA was isolated from tumor tissue using “Total Nucleic 
Acid Isolation Kit” (Ambion, USA). Reverse transcription 
was conducted using PCR test set “High Capacity cDNA 
Reverse Transcription Kit” (Applied Biosystems, USA) 
in a total volume of 20 μl with 1 μl of total RNA. The reverse 
transcription reaction was run under the following condi-
tions: 25 °C — 10 min, 37 °C — 120 min and 85 °C — 5 sec. 
GADPH was used to normalize levels of mRNA for the rela-
tive quantification method of analysis. Sequences of pri-
mers (Applied Biosystems, USA) are shown in the Table 1. 
Primers and TaqMan probes were used at 0.3 μM and 
0.2 μM concentrations, respectively. PCR reaction was 
performed in accordance with such as in the detection 
of MNA. Calculations were performed using the ΔΔCt rela-
tive quantification method. The thresholds and baselines 
were set manually in SDS and Ct values were extracted.
Statistical analysis. All experiments were repeated 
independently at least three times. Gaussian distribution 
of the group was checked with Kolmogorov — Smirnov 
tests. Analysis of the association between the studied 
markers and clinical characteristics of patients was 
performed using U-Mann — Whitney test. Prognostic 
significance of markers was verified with the ROC-curve 
(Receiver Operating Characteristic curve). Event free 
survival was evaluated by Kaplan — Meier estimator, 
statistical significance of parameters differences was 
determined using F-Cox criterion. The impact of gene 
expression in NB patients’ survival was evaluated using 
the Cox proportional hazards regression analysis [14]. 
The data were processed with the software package Sta-
tistica 6.1 using parametric and nonparametric methods 
of statistical analysis and MedCalc 12.1.4.0. The diffe-
rence was considered statistically significant at p < 0.05.
RESULTS AND DISCUSSION
Mutations in the TP53 gene rarely are observed 
in childhood cancer of central and peripheral nervous 
system. In primary NB tumors frequency of its muta-
tion does not exceed 1–2% and 15% in recurrent and/
or progressive tumors. Loss of 17p chromosome region, 
mapping TP53 gene, is more usual for NB [4]. In our 
study no tumor sample with 17p chromosome region 
deletion was found in patients with NB. But we suggest 
that deficiencies in p53 functions may be a conse-
quence of aberrant MDM2 expression showed further.
Patients were dichotomized by age into patients 
younger than 18 months and patients 18 months of age 
and older. Stage was dichotomized for the entire NB co-
hort with respect to metastatic progression (i.e., stage I, 
II, and III vs stage IV). MNA was found in 27.5% NB pa-
tients. These patients were classified as high risk group 
and treated with the relevant protocols. The average age 
of patients with MNA was 29.91 ± 3.59 months. Among 
all patients with MNA 36% of patients were with local-
ized disease stages, 64% — IV stage. The frequency 
of MNA detected in our study (27.5%) did not differ 
from the data obtained by other research groups [2].
We have investigated whether MDM2 overexpression 
was associated with various clinical features (Table 2).
Table 2. Clinical and biological characteristics and MDM2 mRNA expres-
sion in NB tumor samples
№ Clinical and biological features
MDM2 mRNA 
expression
 level, a.u.
1 Biological material
Primary tumor n = 80 (87.9%) 1.29 ± 0.29
Recurrent tumor n = 4 (4.4%) 41.116 ± 25.881
Metastatic foci n = 7 (7.7%) 3.36 ± 0.991
Primary tumors:
2 Age (n = 79) Under 18 months n = 29 (36.7%) 0.82 ± 0.30Over 18 months n = 50 (63.3%) 1.58 ± 0.43
3 Stage (n = 69) I–III n = 32 (46.4%) 0.72 ± 0.31IV n = 37 (53.6%) 2.06 ± 0.542
4 MYCN gene status (n = 78)
Non-amplified n = 56 (71.8%) 0.86 ± 0.2
Amplified n = 22 (28.2%) 2.47 ± 0.93
Note: a.u. — arbitrary units; 1р < 0.001 — significant regarding primary tu-
mors; 2р < 0.001 — significant regarding I–III stages; 3р < 0.03 — significant 
regarding MYCN non-amplified.
MDM2 mRNA expression level was significantly 
higher in recurrent tumors compared to primary tumors 
and metastatic sites (p < 0.001). Primary tumors were 
characterized by the lowest level of MDM2 expression. 
These data do not contradict the findings of other re-
search groups [15], and can testify in favor of the theo-
ry that the inactivation of p53 by MDM2 in NB often 
develops during treatment and may be involved 
in the progression and metastasis of the disease and 
the occurrence of relapses.
In primary tumors the value of MDM2 mRNA ex-
pression varied quite widely, especially depen ding 
on the disease stage and MYCN gene status. MDM2 ex-
pression level was significantly higher in tumor samples 
obtained from patients with disseminated disease stage 
compared with early stages and in patients with MNA 
compared with MYCN-negative tumors. Thus, higher 
MDM2 expression was associated with unfavorable 
clinical NB features (MNA, disease stage), indicating 
a link between MDM2 overexpression and the high-risk 
phenotype.
We conducted ROC-analysis to assess the prognostic 
significance of MDM2 mRNA expression in NB progres-
sion. ROC-analysis is one of the most accurate statistical 
methods to assess the diagnostic and prognostic signifi-
cance of the marker. For patients distribution on groups 
according to MDM2 mRNA expression level we applied 
event free survival rate as the criterion of clinical efficacy. 
As a result, optimal criterion for definition of high and low 
MDM2 mRNA expression level was established, it was 
> 0.0822 a.u. It was found that the area under the curve 
(AUC) was 0.75 (p = 0.001). According to the ROC-analy-
sis (Fig. 2) high MDM2 expression was shown as a marker 
of unfavorable NB and risk of disease recurrence. This 
marker had sufficient sensitivity and specificity and may 
serve as an independent marker of prognosis and strati-
fication of NB patients on risk groups.
To confirm obtained results we have analyzed 
the event free survival of NB patients depending 
on MDM2 mRNA expression level. With this aim all pa-
tients were divided into 2 groups according to MDM2 ex-
pression level (high and low expression) under ROC-
analysis optimal criterion (Fig. 3).
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Fig. 2. ROC curve for MDM2 mRNA expression ratio in primary NB
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Fig. 3. Kaplan — Meier event free survival curves according 
to optimal criterion of MDM2 mRNA expression level in primary 
NB tumors (p < 0.001)
As the result, overexpression of the MDM2 was 
found in 52.5% (42/80) of patients. We have found that 
the high level of MDM2 expression was associated with 
a significant decrease in event free survival of NB pa-
tients, regardless MYCN gene status and disease stage 
(p < 0.001). Accordingly, the rate of 3-year event free 
survival of patients with MDM2 mRNA high expression 
was only 12%, whereas patients with low expression — 
66%. Such a significant difference indicates that this 
marker has substantial role in the pathogenesis and 
progression of NB and MDM2/p53 imbalance leads 
to poor prognosis in patients. As follows, along with 
other clinical features it can be used as prognostic and 
possibly therapeutic approach for treatment optimiza-
tion. In a Cox proportional hazards model of the risk 
factors, high MDM2 expression was an independent 
factor for event free survival of NB patients (р = 0.002, 
CI 95% 1.06–1.30). Therefore, raised MDM2 expres-
sion level is associated with the risk of disease recur-
rence.
Since MYCN oncogene transactivates MDM2 [8, 
11], in NB with MNA, increased expression/acti vity 
of MDM2 could significantly decrease the activity 
of p53, resulting in failure to undergo appropriate 
cell cycle arrest and/or apoptosis. We have analyzed 
changes of MDM2 expression and event free survival 
in tumors with different MYCN gene status.
In determining of optimal criterion for MDM2 mRNA 
expression level by ROC-analysis in MNA group no pre-
cise parameter for distribution on risk groups was estab-
lished. With Cox regression analysis we have found that 
changes in MDM2 expression level in this group does not 
affect event free survival (p = 0.14, CI 95% 0.97–1.26). 
Changes of MDM2 mRNA expression in this group can 
be explained by MDM2/p53 interaction malfunction 
caused by different reasons. Also they may be caused 
by MNA activating effect on MDM2 and MDM2-mediated 
MYCN expression promotion. In any case, this leads 
to poor prognosis; disease progression that often occurs 
even in patients with MNA and low MDM2 gene expres-
sion, indicating the complexity of NB biology.
Particular attention of oncologists and scientists at-
tracts MYCN non-amplified NB, as it has yet to be known 
factors that lead to rapid progression and aggressive 
course of the disease in some patients or spontaneous 
regression and favorable prognosis in others. For this 
NB group (n = 56) with ROC-analysis we have estab-
lished the possibility of MDM2 mRNA expression using 
as prognostic marker and have identified the optimal 
criterion for distribution on favorable/unfavorable prog-
nostic groups (Fig. 4).
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Fig. 4. ROC curve for MDM2 mRNA expression ratio in MYCN 
non-amplified NB
Finally, we investigated the prognostic value 
of MDM2 expression in this group. Kaplan — Meier 
survival curves revealed that the clinical outcome (event 
free survival) was on 64% higher in low MDM2 expres-
sion group compared to high MDM2 expression group, 
p < 0.001 (Fig. 5). Higher than optimal criterion expres-
sion level was detected in 46.4% tumor samples. With 
Cox regression model we have found that changes 
in MDM2 mRNA expression level in MYCN non-amplified 
NB predetermines event free survival (p < 0.05, CI 95% 
1.004–1.59).
0
0
5
0.2
10
Observation time, month
low MDM2 mRNA expression level (< 0.0822 a.u.)
high MDM2 mRNA expression level (> 0.0822 a.u.)
Ev
en
t f
re
e 
su
rv
iva
l
0.4
15
0.7
20 25 30 4035
1
0.1
0.3
0.5
0.9
0.6
0.8
Fig. 5. Kaplan — Meier event free survival curves according 
to optimal criterion of MDM2 mRNA expression level in MYCN 
non-amplified NB (p < 0.001)
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These data suggest that MDM2 can be useful in pre-
diction of NB prognosis and outcome. In MYCN non-
amplified NB regulatory contribution of MYCN is offset. 
In this group, deterioration in disease course of the pa-
tient with high MDM2 mRNA expression is directly con-
nected with dysregulation in MDM2/p53 interaction.
CONCLUSIONS
Our results have shown that MDM2 mRNA ex-
pression is an important factor in NB prognosis. For 
patients that do not show chromosomal rearrange-
ments of TP53 gene locus, elevated expression 
of MDM2 mRNA can serve as an effective and useful 
prognostic marker under certain circumstances. Thus, 
when MDM2 is expressed at the high level in a group 
with MNA, this has a reinforcing effect on the progres-
sion of the disease. Elevated levels of MDM2 in NB with-
out MNA might be used as the significant prognostic 
marker for both, patient stratification on risk groups 
and for treatment optimization.
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